Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1019277

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to expand the range of drugs covered by the New Medicines Scheme in community pharmacies.
tabling member printed	Baroness Jolly
uin	HL11966
answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>There are no current plans to expand the New Medicine Service. All changes to the community pharmacy contractual framework are made following negotiations with the Pharmaceutical Services Negotiating Committee.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:03:35 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4203 label Biography information for Baroness Jolly

1019278

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what impact assessment they have carried out on the possible decommissioning of the Minor Ailments Scheme.
tabling member printed	Baroness Jolly
uin	HL11967
answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>No assessment of the impact of decommissioning of local Minor Ailment Schemes (MAS) has been undertaken nationally. MASs are currently commissioned locally by the National Health Service according to need. A pilot digital minor illness referral service (DMIRS) commenced last year in the North East with direct referrals from NHS 111 to community pharmacy. Building on this three further DMIRS pilots, supported by the Pharmacy Integration Fund, were launched in November 2018, in Devon, London and East Midlands. An evaluation will inform next steps.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:03:05 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4203 label Biography information for Baroness Jolly

1019279

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to expand the number of prescribing pharmacists.
tabling member printed	Baroness Jolly
uin	HL11968
answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>Pharmacists prescribers are currently working across a range of services in both secondary and primary care. As part of a planned programme of expansion, additional pharmacists are being recruited to work in patient facing roles in general practice. They will be treating patients using their expert knowledge of medicines for specific disease areas and they will either be prescribers, or training to become one. As of October 2018, 876 clinical pharmacists have been recruited, and we have been informed by NHS England that it is committed to recruiting an additional 1,950 clinical pharmacists in general practice by 2020/21.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:03:22 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4203 label Biography information for Baroness Jolly

1019280

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy Integration Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how the Pharmacy Integration Fund has been spent; and what plans they have for the future of the fund.
tabling member printed	Baroness Jolly
uin	HL11969
answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>The Pharmacy Integration Fund (PhIF) has been used to support the employment of pharmacists in integrated urgent care, general practice and care homes where their expert knowledge of medicines is helping to ensure the best care for patients. It has also been used to fund pilots of the supply of urgent medicines to patients without the need for a general practitioner appointment as well as the referral of patients, presenting with minor illness, direct from NHS111 or NHS Online to community pharmacy. These programmes are aimed at better utilising the skillset and reach of community pharmacy teams to support the wider health service. They are being underpinned by several new education and leadership programmes which are also being funded by the PhIF.</p><p>The Government remains committed to this programme and we are continuing to invest in the development of community pharmacy through this fund. Most recently, NHS England announced their plans for a new pilot scheme, with investment of £1 million from the PhIF, to develop system leadership within pharmacy. These pharmacy leaders will set the vision for pharmacy and medicines optimisation within their area, and will support the delivery of a NHS Pharmacy and Medicines Optimisation Transformation Plan, making the best use of pharmacy in meeting local and national health priorities.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:02:49 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4203 label Biography information for Baroness Jolly

1019281

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Counterfeit Manufacturing
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to protect patients from counterfeit medicines if the Falsified Medicines Directive ceases to apply in the UK after Brexit.
tabling member printed	Baroness Jolly
uin	HL11970
answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>In the United Kingdom, strict regulatory controls govern the sale, supply, manufacture, distribution and advertising of medicinal products. Although no fatalities in the UK have been attributed to a falsified medicine sourced from the UK regulated supply chain, the potential threat to patient health is recognised and taken seriously across Government.</p><p>The European Union Falsified Medicines Directive (FMD) was adopted in 2011 and introduced new harmonised measures to ensure that medicines in the EU are safe and that trade in medicines is properly controlled.</p><p>The parts of the Directive that have already been implemented – including tougher rules on the control and inspection of producers of active pharmaceutical ingredients – would be converted into UK law through the Withdrawal Act and therefore remain in place after exit.</p><p>The final element of the Directive – the Delegated Regulation for new safety features – is due to come into force in February 2019, including the creation of a central EU data hub. The UK will still be a Member State in February 2019 and will therefore implement the FMD Delegated Regulation in line with our existing obligations.</p><p>In terms of what would happens after the UK exits the EU, during an implementation period the UK would maintain the new safety features and retain access to the EU central data hub, with arrangements beyond the implementation period still subject to negotiation. In the unlikely event the UK leaves the EU in March 2019 with no deal in place, then as stated in the Medicines and Healthcare products Regulatory Agency recent No Deal consultation, we expect the UK would not have access to the EU central data hub, and therefore the proposal is that legal obligations related to this would be removed for actors in the UK supply chain. In the interests of public safety, we would then evaluate the options around a future national falsified medicines framework.</p><p>Whatever the exit scenario, we will continue to ensure that UK patients are able to access the best and most innovative medicines and that their safety is protected.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:19:02 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4203 label Biography information for Baroness Jolly

1019282

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many pharmaceutical manufacturers have guaranteed to hold six weeks' supply of their medicines for the next six months on top of their buffer stocks; and what proportion of pharmaceutical medicines used in the UK are now covered by that guarantee.
tabling member printed	Baroness Jolly
uin	HL11971
answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>The Government has agreed the terms of our exit from the European Union, as set out in the Withdrawal Agreement. The Withdrawal Agreement offers a time-limited implementation period that provides a bridge to the future relationship, allowing business, including the life sciences industry, to continue trading as now until the end of 2020. The supply of medicines and medical supplies would remain unchanged during the implementation period.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019.</p><p>On 23 August 2018, the Department asked suppliers of all prescription-only and pharmacy medicines with an EU/European Economic Area touch point to confirm their contingency arrangements for continued supply to United Kingdom patients beyond 29 March 2019 in the event of a no-deal Brexit and possible delays at the border in the following period.</p><p>To date we have received very good engagement from industry, who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit. However, as our engagement exercise is still on-going we do not yet have final figures to report.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:20:24 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4203 label Biography information for Baroness Jolly

1019290

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 November (HL10893), what is the average cost to the NHS of treating patients with (1) leukaemia, (2) non-hodgkin lymphoma, (3) hodgkin lymphoma, and (4) myeloma.
tabling member printed	Lord Mendelsohn
uin	HL11979
answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>The data is not collected in the format requested.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:17:35 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

1019321

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the findings of the IPPR report entitled Fair funding for mental health, published in October 2018, whether the Government’s NHS Long Term Plan will increase funding for mental health services.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	198184
answer	answer is ministerial correction date of answer 06/12/2018 answer text <p>The Chancellor announced in October that the National Health Service will increase mental health investment by at least £2 billion a year in real terms by 2023/24.</p><p> </p><p>Improving mental health is at the heart of this Government’s agenda and this is another step in our ambition to achieve parity between physical and mental health care.</p><p> </p><p>NHS leaders are producing a new ten-year plan, led by clinicians and professionals, and supported by local health and care systems across the country. We expect the plan to be published later this year and as such decisions are still being taken on the exact content of the plan.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 06/12/2018 17:14:03 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1019322

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Digital's publication, Cervical screening programme England 2017-18, published on 27 November 2018, what assessment he has made of the reasons for the change in the number of eligible women taking up such screening in the last 21 years.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	198377
answer	answer is ministerial correction date of answer 06/12/2018 answer text <p>NHS England has reviewed the data from 2013 showing the continuing gradual national and international decline in the five-year coverage. Assessments for the decline were done in partnership with key stakeholders Public Health England (PHE) and Jo’s Cervical Cancer Trust.</p><p> </p><p>NHS England hosted a spotlight session in April 2016 which focussed on gaining insight into the reasons why women do or do not attend for screening. This suggested that ease of access together with attitudinal changes to informed choice, may contribute to this widespread reduction in uptake.</p><p> </p><p>Jo’s Cervical Cancer Trust published a report in January 2018 suggesting that some young women did not attend cervical screening appointments because they were embarrassed about their body, while others did not think the test was important and were not at risk because they led healthy lifestyles.</p><p> </p><p>NHS England and PHE have therefore modified the commissioning levers and communication processes, for example through supporting Jo’s Trust in the Time to Screen campaign and the development of a new ‘Be Clear on Cancer’ campaign for early 2019 promoting uptake of cervical screening.</p><p> </p><p>NHS England has supported the Cancer Alliances who bring together local senior clinical and managerial leaders representing the whole cancer patient pathway across a specific geography, and have a general role in improving early diagnosis. In turn they have developed specific plans to improve uptake rates in screening programmes as part of that agenda with cervical screening considered a priority area.</p><p> </p><p>Cancer Research UK and Macmillan general practitioners (GPs) are also being utilised to provide awareness and training, with work and focus groups to target reducing inequalities among women over 50 and women from Eastern European countries a specific focus in one region. The role that sexual health clinics can play in providing access to screening among vulnerable women via an opportunistic offer of screening is being considered.</p><p> </p><p>Training of GP receptionists is underway to improve ease of access to a screening appointment, while a toolkit has been developed to reduce the inequality in uptake among women with a learning disability.</p><p> </p><p>In addition, NHS England recently announced that Professor Sir Mike Richards has been asked to lead a review of cancer screening programmes which will consider ways to increase uptake of cervical screening.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/12/2018 14:22:41 answering member 4067 label Biography information for Steve Brine
tabling member	4056 label Biography information for Nic Dakin

1019327

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS Property Board
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the annual cost of the NHS Property Board.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	198379
answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>Chaired by the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the NHS Property Board brings together senior representatives from the Department, NHS England, NHS Improvement, wider government, Community Health Partnerships and NHS Property Services to provide leadership and strategic direction for the system on estates matters.</p><p> </p><p>The NHS Property Board operates using existing resources; no additional funding has been allocated. The Board does not receive funding from non-Departmental sources.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 198380 question first answered 10/12/2018 16:18:46 answering member 1585 label Biography information for Stephen Hammond
tabling member	4444 label Biography information for Karin Smyth